Skip to main content
Premium Trial:

Request an Annual Quote

Nucleix Raises Additional $22M

This article has been updated to correct information about Nucleix's partnership with the MD Anderson Cancer Center.

NEW YORK — Israeli cancer diagnostics developer Nucleix said on Wednesday that it raised $22 million in December, extending a financing round closed earlier last year.

The additional investment was led by Sands Capital and follows a $55 million oversubscribed financing round Nucleix closed in April, bringing the total amount raised by the firm in 2021 to $77 million.

Nucleix is developing liquid biopsy tests for early-stage and recurring cancer diagnosis that use PCR and next-generation sequencing technologies to detect tissue-specific methylation patterns on circulating tumor DNA that can be analyzed using proprietary software.

The company currently markets a bladder cancer recurrence test — called Bladder EpiCheck — in Europe and is awaiting 510(k) clearance from the US Food and Drug Administration for the assay. It has also developed a lung cancer early detection test, called Lung EpiCheck, and is working on another lung cancer test that uses the EpiCheck platform in partnership with the MD Anderson Cancer Center.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.